fbpx

Blog

Free influenza vaccinations from Queensland pharmacists

17 July 2023

 

The Pharmaceutical Society of Australia (PSA) welcomes Queensland Health Shannon Fentiman’s announcement of state-wide, no-cost influenza vaccinations for Queenslanders.

 

PSA Queensland President Shane MacDonald MPS said that the move will encourage more Queenslanders to make influenza vaccination a part of their regular health care.

 

“All Queensland age groups have the lowest or second-lowest influenza vaccination coverage of any state or territory this year,” Mr MacDonald said.

 

“Particularly at risk are young children, of which less than 20 per cent are vaccinated against influenza in 2023. Vaccination rates among Queenslanders aged 5 to 15 years is the lowest in Australia, sitting at just 11.1 per cent.

 

“We have already seen the deadly impact of low vaccination rates across the country, and if we don’t act now it will only get worse.

 

“Removing cost barriers and giving Queenslanders greater access to vaccines through community pharmacies is a great first step to improving vaccine uptake,” Mr MacDonald said.

 

“Pharmacists are able to vaccinate patients 6 months and over, meaning many families can come into their pharmacy together for their flu vaccines.

 

“With the flu season now in full swing, we need to do everything we can to protect Australian children by increasing access to vaccination and providing Queensland families with optimal protection against this deadly disease.

 

“As pharmacists we have demonstrated the crucial role we continue to play in protecting the health of Australians. We must do better than this to protect the most vulnerable in our communities.

 

“Pharmacists are practicing in almost every community from Brisbane to Cape York, supporting the health and wellbeing of our patients.

 

“Our message to all Queenslanders is simple, visit your local pharmacist and get your influenza vaccine,” Mr MacDonald concluded.

 

Data from NCIRS (accessed 17 July 2023)

https://ncirs.org.au/influenza-vaccination-coverage-data

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

 

JOINT MEDIA RELEASE: MSAC support funding pharmacists in First Nations Primary Health Services

 

12 July 2023

 

The Pharmaceutical Society of Australia (PSA) and the National Aboriginal Community Controlled Health Organisation (NACCHO) have welcomed today’s release of Medical Services Advisory Committee (MSAC) advice supporting funding to embed non-dispensing pharmacists within Aboriginal Health Services.

 

Australia’s principal medical advisory group’s recommendation is based on a joint submission from PSA, NACCHO and James Cook University (JCU) calling for funding for the Integrating Pharmacists within Aboriginal Community Controlled Health Services to improve Chronic Disease Management (IPAC) project.

 

The IPAC project integrated 26 pharmacists into 18 Aboriginal Community Controlled Health Organisations for 15 months across Queensland, Victoria, and the Northern Territory. Through the project, some Aboriginal Community Controlled Health Services embedded pharmacists directly into their services, while others worked with community pharmacies to deliver pharmacy services.

 

The independent expert advice recognises the significant impact pharmacists can have when integrated into comprehensive primary healthcare teams.

 

MSAC considered that the model was safe and effective compared to usual care. MSAC considered that the estimated costs for providing this integrated, collaborative, culturally appropriate patient-centred care to improve health outcomes for Aboriginal and Torres Strait Islander peoples was good value for money.

 

NACCHO and PSA are looking forward to working with government on rolling-out this important service nationally. PSA and NACCHO also recognise the leadership of JCU on this work that has led to this successful outcome.

 

Quotes attributable to the Chair of NACCHO Donnella Mills

 

“Aboriginal and Torres Strait Islander peoples continue to experience a higher burden of chronic disease due to cardiovascular, diabetes and other health problems than other Australians. 

 

“We are thrilled that that this independent medical advisory group has officially supported funding for integrating pharmacists into ACCHOs’ model of care.

 

Quotes attributable to PSA National President Dr Fei Sim FPS

 

“Through the IPAC project, pharmacists have proven how valuable we are in improving the health outcomes of Aboriginal and Torres Strait Islander peoples’ health. 

 

“One-third of pharmacists involved in the IPAC project were contracted from community pharmacies, highlighting further opportunities for capacity building initiatives within the pharmacy sector to collaboratively deliver better health outcomes for Aboriginal and Torres Strait Islander people.

 

“PSA is proud to have co-designed the Deadly pharmacists: foundation training for pharmacists working within Aboriginal Community-Controlled Health Services, which more than 900 pharmacists have accessed since its launch in late 2022, but we must continue to work together to improve health outcomes for Aboriginal and Torres Strait Islander people.

 

Quotes attributable to the Chair of NACCHO Donnella Mills

 

“Having the support of MSAC confirms when pharmacists are present within our services, both patients and staff at the clinic are better supported to provide safe and effective use of medicine. 

 

“Our member services have been calling for support and funding for non-dispensing pharmacists integrated into ACCHOs for years, this endorsement further validates their requests and demonstrates the impact of team-based community-controlled healthcare.

 

“Now that support for funding for pharmacists integrated into ACCHOs has been provided through the advisory committee, we look forward to working with government on how it can be rolled-out nationally.”

 

Quotes attributable to PSA National President Dr Fei Sim FPS

 

“Both NACCHO and PSA are ready and willing to work with the Federal Government to implement a collaborative model of care which meets the needs of the Aboriginal and Torres Strait Islander people and is consistent with the Federal Government’s commitment to the Priority Reforms of the National Closing the Gap Agreement.”

 

 

Media Contacts:

 

Georgia Clarke (PSA)  M: 0410 505 315     E: georgia.clarke@psa.org.au

Verity Leach (NACCHO) M: 0438 944 113 E: Verity.Leach@naccho.org.au

Pharmacists now able to dispense medical terminations medicines across Australia

11 July 2023

 

The Pharmaceutical Society of Australia (PSA) welcomes the Therapeutic Goods Administration’s decision to remove restrictions that prevent health professionals, including doctors and pharmacists, from prescribing and dispensing MS-2 Step (mifepristone and misoprostol).

 

From 1 August 2023, pharmacists will no longer need to be registered or undertake specific training to dispense MS-2 Step to patients across Australia.

 

PSA National President Dr Fei Sim FPS welcomes the move, noting that it will significantly improve women’s access to healthcare.

 

“This move will improve the access to care for women, making MS-2 step available in more pharmacies and in more communities in Australia.

 

“This approach recognises that pharmacists are medicine experts, and that dispensing MS-2 Step and counselling patients on its use is already within the scope of practice of pharmacists.

 

“By removing unnecessary red tape, pharmacists can help more Australian women access reproductive care, in line with international experience.

 

“Pharmacists follow a robust process to ensure all medicines are dispensed safely and effectively.

 

“Community pharmacists are the most accessible healthcare professional for many Australians and play a critical role to ensure women’s equitable access to reproductive care, especially in rural and remote areas.

 

“As the Co-Chair of the Access, Care and Outcomes Subcommittee of the National Women’s Health Advisory Council chaired by Assistant Minister for Health and Aged Care Ged Kearney, I welcome this TGA decision to improve women’s access to reproductive care.”

 

 

Media contact:   Georgia Clarke  

M: 0480 099 798  E: georgia.clarke@psa.org.au

Health Minister Mark Butler to open PSA23

5 July 2023 

 

The Pharmaceutical Society of Australia (PSA) has today announced that Federal Minister for Health and Aged Care the Hon Mark Butler MP will attend PSA23 in Sydney on 28 July 2023.

 

PSA23 is Australia’s leading education conference for pharmacists, attended by hundreds of industry leaders, academics and researchers, and pharmacists from all practice settings.

 

PSA National President Dr Fei Sim FPS said that there had never been a more important time for the Minister to address pharmacists.

 

“I am pleased to confirm that Minister Butler will address pharmacists directly as part of PSA23,” Dr Sim said.

 

“This will be the first time that Minister Butler addresses pharmacists since he announced the introduction of 60-day dispensing in April.

 

“PSA23 will be an opportunity for pharmacists to hear directly from the Minister for Health and Aged Care, as well as the Assistant Minister for Rural and Regional Health Emma McBride on the significant policy changes impacting our profession.”

 

PSA23 will see attendance from both sides of politics. Shadow Minister for Health and Aged Care Senator Anne Ruston will also be addressing attendees on Saturday 29 July.

 

For more information on PSA23 and the conference program, visit www.psa23.com.au

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

ACT Pharmacists win expanded scope

27 June 2023

 

The Pharmaceutical Society of Australia’s (PSA) campaign to expand scope of practice for pharmacists paid off this week, with new authorisations announced by the ACT Government.

 

Under yesterday’s legislative update, pharmacists in the ACT are authorised to administer medicines for injection, including Long-Acting Injectable Buprenorphine (LAIB).

 

The PSA’s ACT Branch President Olivia Collenette said the landmark change, which would enhance patient access to vital injectable medications, came after a lot of campaigning.

 

“We have long championed expansion of pharmacist scope of practice and, while there is still a long way to go, this is a significant step,” she said.

 

“We are thrilled that our advocacy on this particular issue has borne fruit, signalling a brighter future for pharmacy and reinforcing our commitment to advancing patient-centred care.”

 

The PSA has already provided comprehensive training on administering medicines by injection.

 

Pharmacists are encouraged to access these resources to ensure they are equipped with the necessary knowledge and skills to provide optimal care.

 

“PSA encourages all pharmacists in the ACT to familiarise themselves with the updated regulations and embrace this progressive expansion of their professional capabilities,” Ms Collenette said.

 

“By staying informed and ensuring adherence to best practices, pharmacists will continue to play a pivotal role in enhancing patient outcomes and promoting public health.”

 

For more information on the administration of medicines for injection by pharmacists in the ACT, visit:

 

Pharmacist Vaccinations and Injectables | Health (act.gov.au)

 

 

Protected: PSAmplified Hot Issues

This content is password protected. To view it please enter your password below:

Students to compete at National Pharmacy Competition (PSOTY)

23 June 2023

 

The Pharmaceutical Society of Australia (PSA) today announced the state and territory finalists for the 2023 Viatris Pharmacy Student of the Year (PSOTY) award, with the prestigious national final to take place at PSA’s National Conference PSA23 in July.

 

During the national final, students will be tested with a real-life clinical situation, where a patient will present with symptoms or a specific product request. Students are then required to use their clinical knowledge and communication skills to identify the most appropriate course of over-the-counter treatment, tailoring their response to provide the most appropriate advice.

 

A judging panel assesses all state finalists before selecting the national winner to be announced at PSA23’s Gala Dinner.

 

PSA National President Dr Fei Sim FPS congratulated the finalists, saying that the awards encourage students to draw on their clinical knowledge and emotional intelligence to demonstrate their skills.

 

“The Pharmacy Student of the Year awards showcase the skills and abilities of some of our outstanding pharmacy students to the broader profession, while also giving students a chance to apply their skills and be judged on them.

 

“Award sponsor Viatris and PSA are proud to sponsor the finalists to attend PSA23, providing travel and accommodation to ensure that they can get the most out of the leading pharmacist education conference.

 

“The Pharmacy Student of the Year will also receive a $3,000 cash prize to support their studies and pharmacy careers.

 

“Congratulations to all the students who’ve participated in the competition this year for their hard work and commitment to pharmacy.

 

“It’s exciting to see such talented students entering our profession and dedicating their lives to the health and wellbeing of their communities,” Dr Sim said.

 

The 2023 PSA Viatris Pharmacy Student of the Year finalists are:

  • Jamie-Lee Carew, the University of Newcastle
  • Sarah Foster, LaTrobe University
  • Kennith Lam, Curtin University
  • Samantha Montgomery, Queensland University of Technology
  • Claire Ryan, University of Tasmania
  • Brett Spicer, University of Canberra
  • Amelia Thompson, University of South Australia

 

 

They will also be joined by Ingrid Stoud from the University of Canberra, who was awarded the Wildcard winner at the 2023 National Australian Pharmacy Students Association Congress in January.

 

PSA extends thanks to the PSOTY award sponsor, Viatris, for their ongoing support and wishes all finalists the best of luck at the national final.

 

Find out more about the PSA Pharmacy Student of the Year competition by visiting www.psa.org.au/psoty 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

 

 

Australia cannot afford cuts to pharmacy: report

19 June 2023

 

A new independent report released this morning has highlighted the enormous impacts of 60-day dispensing on the pharmacy sector.  

 

The report from economist Henry Ergas AO with Tulipwood Advisory and the Relational Insights Data Lab at Griffith University, found that more than 20,000 community pharmacy jobs would be lost over the next four years.  

 

On top of job losses, Mr Ergas found that more than 650 pharmacies would close and a further 900 would be at risk of closing due to financial pressures as a result of 60-day dispensing policies introduced this year.  

 

Key findings from the report include: 

 

  • Up to 20,818 community pharmacy jobs could be lost over four years. 
  • Up to 665 community pharmacies could close, with a further 900 at risk of closure due to financial stress. 
  • Free services could be cut, including blood pressure monitoring and weight checking as part of diabetes programs, home delivery of medication, asthma monitoring, extended medicine management (on average each pharmacy delivers 20 or more free consultations each day). 
  • Cuts will disproportionally impact vulnerable communities, including the elderly and Australians living with chronic health conditions. 
  • Regional and rural pharmacies will be the first to close, disproportionately impacting First Nations Australians.  
  • More than $4.5 billion will be cut from community pharmacies over four years. 
  • $2.5 billion cost to Australian health system due to increased hospitalisations from medicine misadventure. 

 

The Pharmaceutical Society of Australia (PSA) National President Dr Fei Sim FPS said the report’s findings were disturbing. 

 

“The report’s key findings highlight just how pervasive the impact of 60-day dispensing will be, not only on the viability of community pharmacy, but also on the availability of accessible healthcare for Australians,” Dr Sim said.  

 

“This is the first economic modelling we’ve seen that looks at the flow-on effects of 60-day dispensing, and the results are scary. 

 

“Pharmacists are an integral part of our primary healthcare system, and with medicine use on the rise we cannot afford to lose billions from our sector. 

 

“The 2019 Medicine Safety: Take Care report found that 50 per cent of medicine related harm was preventable, which will no doubt rise without pharmacists available to support communities.  

 

“All pharmacists support making medicines more affordable, but it cannot come at the expense of medicine safety, a cost that will be worn by our most vulnerable groups. 

 

“We need to understand that these impacts are significant. We need to genuinely sit down and plan a way forward for patients, the pharmacy sector, and for the government.  

 

“We want a solution that allows us to continue providing accessible health care to our communities and supporting their safe and effective use of medicines,” Dr Sim concluded.
 

In the report, Henry Ergas AO says: 

 

  • “It would seem sensible for the next steps to be suspend the implementation of the first tranche of the MDQ policy change…until an evidence-based, independent review of the financial and economic impacts on the community pharmacy sector and the Australian community more broadly is undertaken and the impacts properly understood”. 
  • “As a key part of this independent analysis… engage in meaningful consultation with all stakeholders in the community pharmacy sector (peak bodies, consumer bodies and individual pharmacists across all of Australia’s diverse regions) so as to properly test the impacts of the MDQ policy change at the individual community pharmacy level, at regional levels, and at a national level”. 

 

The full report can be found here. 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au 

Pharmacists and health leaders recognised in King’s Birthday Honours

12 June 2023

 

Dr Fei Sim FPS, National President of the Pharmaceutical Society of Australia (PSA), extends her warmest congratulations to three distinguished pharmacists and PSA members who have been recognised in today’s King’s Birthday Honours for their outstanding contributions to the pharmacy profession and community.

 

PSA Life Fellow Associate Professor Louis Roller AM FPS has been recognised for his significant service to the pharmacy profession through education and governance. Dr Sim highlights Assoc. Prof. Roller’s invaluable contributions to the advancement of pharmacy education and his tireless efforts to improve the standards of pharmacy practice.

 

“Assoc. Prof. Roller’s exceptional dedication to education and governance has had a profound impact on the pharmacy profession for decades. His passion for knowledge-sharing and commitment to excellence is truly commendable,” Dr Sim remarked.

 

PSA Life Member Mr Kerry Schiemer OAM MPS, a longstanding contributor to the pharmacy profession has also been recognised for his service to aviation. Dr Sim commends Mr Schiemer’s unwavering commitment to providing quality care and enhancing the health outcomes of patients.

 

“Mr Schiemer’s tireless efforts and exemplary service reflect the very essence of our profession. We are proud to see his contributions recognised with this prestigious honour,” said Dr Sim.

 

PSA member and esteemed pharmacist from Queensland, Mr Brett Clark AM MPS has been honoured for his remarkable service to community health, the arts, and sports organisations. As the Founder and Managing Director of ePharmacy since 2005 and the Managing Partner of Chemist Warehouse since 2005, Mr Clark has made significant contributions to improving healthcare access and promoting the well-being of communities.

 

“Mr Clark’s entrepreneurial spirit and unwavering dedication have transformed the landscape of community health. His excellent leadership and dedication to serving others have left an indelible mark,” Dr Sim said.

 

PSA would also like to acknowledge the remarkable contribution of the following health leaders to their respective fields –  Professor David Craik, Professor Michael Kidd, Dr Anna Lavelle and Professor Danielle Mazza.

 

“Professor Craik’s pioneering work in the Victorian College of Pharmacy had a profound impact on the profession. His commitment to education and mentorship has inspired countless researchers and pharmacists,” said Dr Sim.

 

“Professor Michael Kidd has made invaluable contributions throughout the pandemic, demonstrating exceptional leadership and expertise in medical administration and community health.

 

“Dr Anna Lavelle’s significant service to science and innovation, exemplified through her various roles, including her position as the Chair of Medicines Australia since 2018, has been truly commendable.

 

“Professor Mazza’s commitment to women’s health and her research achievements have made a significant impact on healthcare in Australia.

 

Dr Sim expresses her heartfelt congratulations to all receiving well-deserved honours today. Their exceptional achievements and commitment to excellence inspire pharmacists across the nation to strive for greatness in their profession.

 

60-day dispensing

To inform our ongoing advocacy and feedback to the Department about this policy, PSA has also established a dedicated contact for members to raise concerns and issues directly with our team.

 

If you have any examples of unintended consequences or issues as a result of the 60-day prescription policy,  please send an email to 60daydispensing@psa.org.au. This will help gather evidence on the impact on the ground.

 

If you are concerned about the clinical appropriateness of 60-day prescriptions – contact the prescriber in the first instance.

 

If you need professional advice – please call the PSA Pharmacist-to-Pharmacist advice line where one of our expert senior pharmacists will be able to help.

 

The Pharmacist-to-Pharmacist advice line is available exclusively to PSA members, providing confidential, independent and specialised advice to support and guide your practice, referencing the most up-to-date standards, guidelines and resources developed by PSA and regulatory bodies.

 

Contact the Pharmacist-to-Pharmacist Advice Line on 1300 369 772 – Option 5, between 8.30am and 5.00pm AEST Monday to Friday, or via P2Padvice@psa.org.au.

Stage 1 includes 92 medicines (256 PBS items) and represents roughly one third of all the medicines proposed to be made eligible for 60-day prescriptions. The 256 PBS items include different dosage forms and strengths of Stage 1 medicines.

 

The list of the Stage 1 medicines is available here.

 

Australian Pharmacist has published a thorough practice update.

 

Members who require further support to transition to 60-day dispensing have access to PSA’s dedicated Pharmacist-to-Pharmacist Advice Line for professional and practice support.

 

1300 369 772

 

 

 

Resources

 

PSA is also continuing our efforts on ensuring there is meaningful reinvestment into our profession to enable pharmacists to continue to deliver high quality healthcare to Australians.

 

This is no doubt a challenging and emotional time for many of us. Please continue to look after yourself and others around you.  If you require support, the Pharmacists’ Support Service is also available on 1300 244 910.

Previous updates

Securing pharmacy’s future

14 July 2023

 

We have so far met with around 30 MPs and senators, as well as the Department of Health. In these meetings, we raised our concerns about the 60-day dispensing policy and aged care program, and put forward recommendations on away forward and how meaningful reinvestment can be undertaken to maintain viability of the community pharmacy network.

 

The way forward must acknowledge the:

  1. real impact of this policy on our profession, patients and health system
  2. essential role that community pharmacies and pharmacists play in primary care

 

Our message and conversations are clear, that the reinvestment should support pharmacy programs with a focus on accessible care and safe and effective use of medicines. This can include services such as triage and referral/minor ailments programs, removing caps on medication reviews and DAAs, and allowing pharmacists to have greater autonomy to utilise our clinical judgements.

 

The proposed reinvestment can only be considered meaningful if the needs of the vulnerable and specific patient groups are addressed. These include older Australians on multiple medications, patients on dose administration aids, people living in rural and remote communities, First Nations people, clients receiving Home Care Packages and people living with disability and chronic debilitating health conditions.

 

The implementation or uptake of any new programs may take time, and therefore safeguards must be in place to maintain viability of the community pharmacy network and ensure good patient care through optimising the role of pharmacists in primary healthcare delivery. As such, there may be a need to review and increase dispensing and AHI fees, or the acceleration of new service implementation.

 

On aged care, we continue to advocate for flexibility in service administration and delivery, and maximising pharmacists’ time on ground to deliver resident-level and facility-level duties to meet the recommendations of the Royal Commission into Aged Care Quality and Safety.

 

We have also raised our strong concern that the current proposal (through community pharmacy however without any remuneration for pharmacy engagement) will see significant implementation challenge in terms of uptake and equity. We are continuing our conversations with the Department, with more meetings to come.

 

Dr Fei Sim FPS

PSA National President

Support us to support you – Update on Senate Estimates

2 June 2023

 

Last week, the Senate’s Community Affairs Committee held hearings to discuss the Federal Budget measures impacting our profession. I wanted to provide you with an update on these proceedings and highlight the important role that the Pharmaceutical Society of Australia (PSA) plays in advocating for pharmacists like you.

 

Alongside our members, PSA has been working tirelessly, in collaboration with other pharmacy organisations who share similar concerns, to represent your interests and to ensure your voice is heard. It was clear that our concerns are being heard.

 

Recent policy developments highlight the importance of unity and strong representation for all pharmacists. In crucial times like this, it is vital that our profession stays united in solidarity. As PSA’s National President, I am absolutely committed to advocating for your interests. I invite you to join me, our PSA elected officials, members and team, in our shared mission to enable pharmacists to be at the forefront of healthcare in Australia.

 

During the hearings, the committee questioned officials from the Department of Health regarding various policy measures, including the proposed 60-day dispensing, on-site aged care pharmacist program, and community pharmacy reinvestment.

 

Senate Estimates highlighted the impact of these proposed policies, with Senators referencing conversations with pharmacists. The discussions covered a wide range of topics, such as medicine shortages, pharmacy viability (especially in regional areas), aged care services, medicines wastage, safety considerations, and policy implementation approaches.

 

Department heads were asked to respond to a number of questions on topics ranging from medicine shortages, the viability of pharmacies – particularly in regional areas – aged care, medicines wastage, impact on safety, “reinvestment” and policy implementation approach. Senator Anne Ruston questioned the consultation and decision-making process, and the $1.6 billion loss in co-payments.

 

Much of the testimony explored details already on the public record, however additional insight was provided in some areas. For example, on aged care, the Department was asked to reflect on concerns that pharmacies have been providing DAAs to residential aged care facilities cross-subsidised by dispensing remuneration and that this may no longer be sustainable. Department of Health Deputy Secretary Penny Shakespeare noted that it is not an expectation that pharmacies provide free services to aged care facilities and that there is a willingness to consider ways to manage this impact.

 

In relation to 60-day dispensing, the Department has also:

  • Confirmed a substantial component of the “reinvestment” in community pharmacy will be used to top-up budgeted funds for professional services within the 7CPA.
  • Recognised there may be an increase in medicines wastage, but have described the likely impact as small in the context of the scale of the PBS and that they intend to monitor this via the RUM program.

 

In response to questions from ACT independent Senator David Pocock, the Department of Health described some of the remuneration and transition arrangements for opioid dependence program:

  • Patients will pay a PBS co-payment for the medicine (i.e., methadone or buprenorphine), but be subject to no additional charges.
  • Like other S100 HSD medicines, community pharmacies will be paid a markup, dispensing fee, and Dangerous Drug fee for the dispensing of this item.
  • A staged supply fee of $5.66 (including a $0.97 consumables allowance) will be provided for each dose provided by a pharmacist.
  • The Department is exploring transition arrangements so that existing prescriptions can be used for a period following the program’s start date.
  • The Department is exploring some transition arrangements for availability of OTP medicines for private clinics, but reaffirmed the policy intention is to reduce out-of-pocket patient costs.

 

On other measures discussed:

  • Following Minister Butler’s announcement of a scope of practice review for all health professionals, Department of Health Deputy Secretary Penny Shakespeare provided the committee with an update on preparation for the review. The Department is currently preparing the Terms of Reference for the review which will take 12-18 months to complete.
  • In response to questions regarding vaping reforms, Department of Health Secretary Brendan Murphy indicated that non-prescription supply of nicotine-vapes for smoking cessation by pharmacists is a policy option the TGA is considering.

 

Please let me emphasise that the momentum of our advocacy efforts must continue if we want to ensure there is meaningful reinvestment into our profession as a pathway forward, to maintain the career prospects of our pharmacists and the viability of the community pharmacy network. Pharmacists can do more, the health system and our patients need pharmacists to do more, but pharmacists can’t do more for less.

 

As a valued member of our esteemed FB ECP group, I thank you for being part of our dynamic community that is shaping the future of pharmacy. Your dedication and passion are instrumental in driving the progress of our profession.

 

For those who are already PSA members, I appreciate your continued support and commitment to your professional growth. Your membership enables PSA to provide you with exclusive resources, networking opportunities, and tailored support to help you thrive as an early career pharmacist.

 

To those who haven’t yet joined us, I invite you to embark on this exciting journey with the Pharmaceutical Society of Australia (PSA). Renew your membership today or join us for the first time by visiting PSA Membership or emailing membership@psa.org.au. Together, lets forge a better future for our profession.

 

If you have any questions or any feedback, feel free to reach out to our team on 1300 369 772.

 

Best wishes,

 

Dr Fei Sim FPS

PSA National President